These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 3963858

  • 1. [The clinical value of long-term administration of OK-432 in head and neck cancer].
    Mitarai K, Tsukuda M, Tamamushi N, Mochimastu I, Kubota A, Sawaki S.
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):945-50. PubMed ID: 3963858
    [Abstract] [Full Text] [Related]

  • 2. [Immunotherapy, with OK-432 for cases of nasopharyngeal carcinoma].
    Tsukuda M, Tamamushi N, Mochimatsu I, Mitarai K, Kaneko M, Sawaki S.
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):53-9. PubMed ID: 3942399
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Adjuvant immunochemotherapy with long-term OK-432 administration in colorectal cancer].
    Kikkawa N, Sasai H, Kawahara T.
    Gan To Kagaku Ryoho; 1984 Oct; 11(10):2163-9. PubMed ID: 6486832
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Clinical study on the effect of adjuvant immunochemotherapy using OK-432 and 5-FU in pharyngeal and laryngeal cancers].
    Yajin K, Harada Y, Tagashira N, Suzuki M, Hirakawa K, Sera K, Nakata M, Takebayashi S, Okazaki H, Yashiki T.
    Gan To Kagaku Ryoho; 1988 Jun; 15(6):1921-7. PubMed ID: 3289502
    [Abstract] [Full Text] [Related]

  • 8. [Relation between prognosis and the Su-PS skin reaction in patients with non-resected primary lung cancer receiving OK-432].
    Nakarai I, Rikitake H, Koga T, Hayashi A, Harada Y, Takamoto M, Ishibashi T, Shinoda A, Sagawa K.
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3050-7. PubMed ID: 2823723
    [Abstract] [Full Text] [Related]

  • 9. Immunological differences between squamous cell cancer patients treated with and without biological response modifier (OK-432): evaluation at a period of more than one year after the last treatment.
    Yoshimura Y, Oka M, Harada T, Inou Y, Saito H, Odagawa T, Matsumoto K.
    J Osaka Univ Dent Sch; 1989 Dec; 29():117-22. PubMed ID: 2577382
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [A double blind study of the evaluation of the optimal dose and its frequency in oral administration of OK-432 (Picibanil) by immunological parameters (the 1st report)].
    Shiraishi T, Nio Y, Imai S, Tsubono M, Morimoto H, Tseng CC, Tobe T, Tanaka T, Kitamura O, Sakanashi S.
    Nihon Gan Chiryo Gakkai Shi; 1990 Apr 20; 25(4):799-811. PubMed ID: 2196311
    [Abstract] [Full Text] [Related]

  • 12. [Evaluation of various administration routes of the streptococcal preparation, OK-432, with regard to their in vivo effect by lymphocytes proliferation assay].
    Kimura Y, Toki H, Okabe K, Fujii M, Tamai M.
    Gan To Kagaku Ryoho; 1986 Jan 20; 13(1):95-100. PubMed ID: 3942400
    [Abstract] [Full Text] [Related]

  • 13. [Clinical investigation of intratumoral OK-432 administration].
    Shimada K, Tabuse K, Kono N, Katsumi M, Yamamoto H, Yamamoto Y, Endo A.
    Gan To Kagaku Ryoho; 1983 Aug 20; 10(8):1844-9. PubMed ID: 6882008
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [The alternation of peripheral lymphocyte subsets in head and neck carcinoma].
    Mitarai K, Tsukuda M, Mochimatsu I, Kubota A, Sawaki S.
    Gan No Rinsho; 1986 Jul 20; 32(8):849-54. PubMed ID: 3747146
    [Abstract] [Full Text] [Related]

  • 16. [Effect of immunotherapy using the non-specific immunopotentiator OK-432 in malignant ovarian tumors--selecting appropriate cases for immunotherapy].
    Nishida Y, Sakakibara K, Kano T, Ohta M, Tomoda Y.
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jul 20; 38(7):1017-25. PubMed ID: 3746020
    [Abstract] [Full Text] [Related]

  • 17. [Clinical significance of a skin test (SU-PS) for immune responses in patients with gastrointestinal cancer treated with OK-432].
    Miyamoto Y, Takeshita M, Izuo M.
    Gan To Kagaku Ryoho; 1986 Oct 20; 13(11):3229-35. PubMed ID: 3777960
    [Abstract] [Full Text] [Related]

  • 18. [Clinical studies of long-term administration of OK-432 in patients with gynecologic cancer].
    Mano T, Kawamoto K, Miyake T, Torigoe T.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep 20; 41(9):1439-45. PubMed ID: 2685142
    [Abstract] [Full Text] [Related]

  • 19. [The effect of OK-432 in the treatment of primary lung cancer].
    Kishimoto T, Okada K.
    Gan To Kagaku Ryoho; 1987 Apr 20; 14(4):1051-6. PubMed ID: 3494430
    [Abstract] [Full Text] [Related]

  • 20. Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer.
    Kimura T, Suzuki K, Motai H, Miyamoto N, Tsuge I, Ito Y, Baba S.
    Acta Otolaryngol Suppl; 1996 Apr 20; 525():135-41. PubMed ID: 8908288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.